Business Segments Quoin Pharmaceuticals, Ltd.
Equities
QNRX
US74907L4095
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.890 USD | -1.33% |
|
+1.02% | -60.97% |
| 07-08 | Quoin Pharmaceuticals & CFO Gordon Dunn agree to a mutual separation | RE |
| 07-08 | Quoin Pharmaceuticals Ltd. Announces Mutual Separation with CFO Gordon Dunn | CI |
Sales 2024 by Business Segment
Sales 2024 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
Biological Products | ||||||
Total Assets | 1.38M | 9.36M | 14.46M | 12.17M | 15.71M | |
Interest Expense | -47.02K | -1.37M | -714K | - | - | |
EBT | -2.1M | -21.46M | -9.38M | -8.69M | -8.96M | |
D&A | 104K | 104K | 104K | 104K | 100K | |
Net Income | -2.1M | -21.46M | -9.38M | -8.69M | -8.96M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
- Stock Market
- Equities
- QNRX Stock
- Financials Quoin Pharmaceuticals, Ltd.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition